🇺🇸 FDA
Patent

US 10876116

Anti-ARID3a treatments for inflammatory disorders

granted A61PA61P31/12A61P37/02

Quick answer

US patent 10876116 (Anti-ARID3a treatments for inflammatory disorders) held by The Board of Regents of the University of Oklahoma expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Oklahoma
Grant date
Tue Dec 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61P, A61P31/12, A61P37/02